Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy
In December, 2019, reports emerged from Wuhan, China, of a severe acute respiratory
disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By the …
disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By the …
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development
P Spagnolo, JA Kropski, MG Jones, JS Lee… - Pharmacology & …, 2021 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown cause
characterized by relentless scarring of the lung parenchyma leading to reduced quality of life …
characterized by relentless scarring of the lung parenchyma leading to reduced quality of life …
Idiopathic pulmonary fibrosis
DJ Lederer, FJ Martinez - New England Journal of Medicine, 2018 - Mass Medical Soc
Idiopathic Pulmonary Fibrosis | NEJM Skip to main content NEJM Group Follow Us Facebook
Twitter Instagram YouTube LinkedIn Prepare to become a physician, build your knowledge …
Twitter Instagram YouTube LinkedIn Prepare to become a physician, build your knowledge …
Therapeutic targets for cardiac fibrosis: from old school to next-gen
Cardiovascular diseases remain the leading cause of death worldwide, with pathological
fibrotic remodeling mediated by activated cardiac myofibroblasts representing a unifying …
fibrotic remodeling mediated by activated cardiac myofibroblasts representing a unifying …
Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis: a systematic review and meta-analysis
Background Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung
disease associated with significant morbidity and mortality. Nintedanib and pirfenidone are …
disease associated with significant morbidity and mortality. Nintedanib and pirfenidone are …
Idiopathic pulmonary fibrosis (IPF): an overview
SL Barratt, A Creamer, C Hayton… - Journal of clinical …, 2018 - mdpi.com
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterised by chronic,
progressive scarring of the lungs and the pathological hallmark of usual interstitial …
progressive scarring of the lungs and the pathological hallmark of usual interstitial …
The therapy of idiopathic pulmonary fibrosis: what is next?
V Somogyi, N Chaudhuri, SE Torrisi… - European …, 2019 - Eur Respiratory Soc
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung
disease, characterised by progressive scarring of the lung and associated with a high …
disease, characterised by progressive scarring of the lung and associated with a high …
Lung transplantation for idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a poor prognosis.
Lung transplantation is the only intervention shown to increase life expectancy for patients …
Lung transplantation is the only intervention shown to increase life expectancy for patients …
Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a …
TM Maher, EM van der Aar, O Van de Steen… - The Lancet …, 2018 - thelancet.com
Background Idiopathic pulmonary fibrosis (IPF) causes irreversible loss of lung function.
People with IPF have increased concentrations of autotaxin in lung tissue and …
People with IPF have increased concentrations of autotaxin in lung tissue and …
Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease where invasive
pulmonary myofibroblasts secrete collagen and destroy lung integrity. Here, we show that …
pulmonary myofibroblasts secrete collagen and destroy lung integrity. Here, we show that …